We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Specific Molecule Detected in Bloodstream of Lung Cancer Patients

By LabMedica International staff writers
Posted on 29 Sep 2011
A specific small ribonucleic acid (microRNA) molecule is often elevated in lung cancer patients.

Biological engineers and medical scientists at the University of Missouri (MU; Columbia, MO, USA) used blood plasma samples to detect the change in the microRNA molecule that is often elevated in lung cancer patients. More...
They put an extract of blood plasma through a protein-based nanopore, which is a tiny hole in a thin membrane that is just big enough for a single molecule to pass through. By applying an ionic current to the nanopore, the scientists succeeded in measuring changes in the current that occur when the microRNA molecule associated with lung cancer is present. The study was published in Nature Nanotechnology on September 4, 2011.

"Early detection can save lives, but there is currently no proven screening test available for lung cancer," commented Michael Wang, MD, PhD, assistant professor of pathology and anatomical sciences at the University of Missouri (MU; Columbia, MO, USA) and a corresponding author for the article. "We've developed highly sensitive technology that can detect a specific molecule type in the bloodstream when lung cancer is present."

Li-Qun Gu, PhD, associate professor of biological engineering at MU added that the altered current acts as a signal or bio-signature that is related to lung cancer. "Our new nanopore sensor is selective and sensitive enough to detect microRNAs at the single molecular level in plasma samples from lung cancer patients."

"While there are many research labs that focus on nanopore applications, this is the first time that nanopore technology has been used to detect lung cancer," Prof. Gu added. "This technology could possibly be used in the future to detect other cancer types as well as other types of diseases with specific DNA or RNA in the blood."

Related Links:

University of Missouri
University of Missouri–Pathology and Anatomy






Gold Member
Respiratory Syncytial Virus Test
OSOM® RSV Test
Portable Electronic Pipette
Mini 96
Gold Member
Hematology Analyzer
Medonic M32B
Capillary Blood Collection Tube
IMPROMINI M3
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: New evidence shows viscoelastic testing can improve assessment of blood clotting during postpartum hemorrhage (Photo courtesy of 123RF)

Viscoelastic Testing Could Improve Treatment of Maternal Hemorrhage

Postpartum hemorrhage, severe bleeding after childbirth, remains one of the leading causes of maternal mortality worldwide, yet many of these deaths are preventable. Standard care can be hindered by delays... Read more

Immunology

view channel
Image: When assessing the same lung biopsy sample, research shows that only 18% of pathologists will agree on a TCMR diagnosis (Photo courtesy of Thermo Fisher)

Molecular Microscope Diagnostic System Assesses Lung Transplant Rejection

Lung transplant recipients face a significant risk of rejection and often require routine biopsies to monitor graft health, yet assessing the same biopsy sample can be highly inconsistent among pathologists.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.